[Special Stock] Tegosience Confirms World's First Regenerative Effect of Allogeneic Cell Therapy... Starting to Capture 13 Trillion Won Market

[Asia Economy Reporter Hyungsoo Park] Tegosience has recently been gaining attention in the domestic stock market. The government’s decision to support the clinical trials of the rotator cuff tear cell therapy developed by Tegosience is influencing the stock price with expectations of an increase in corporate value.

At 11:01 AM on the 9th, Tegosience was trading at 31,300 KRW, up 14.65% from the previous day. It had risen to the daily price limit the day before.

Cell therapy developer Tegosience is developing an allogeneic rotator cuff tear cell therapy (TPX-115) made using donor skin cells. Cell therapy involves using cells as therapeutic agents like medicines, injecting them into patients to replace or regenerate cells. Tegosience is developing therapies using differentiated somatic cells. It is the world’s first attempt to create an allogeneic rotator cuff tear cell therapy.

At a corporate presentation (IR) on the 4th, Tegosience introduced that all subjects in the phase 1 clinical trial showed clear effects. The clinical trial verified not only general pain relief and functional improvement but also fundamental structural improvement effects through MRI.

On April 27, Tegosience announced that it was selected as a national project for stem cell and regenerative medicine commercialization through company-led clinical trials (SIT) in 2020. They are conducting phase 1/2 clinical trials of TPX-115, an allogeneic cell therapy for partial rotator cuff tears, aiming for advanced clinical trials and product approval. It is also expected to address unmet medical needs by fundamentally treating the torn shoulder tendon area.

Rotator cuff tears account for about 70% of shoulder lesion patients. With the aging society and an increase in leisure sports activities, the incidence rate is rapidly rising. The number of domestic patients increased from about 550,000 in 2014 to about 770,000 in 2018. The overseas market size reaches approximately 13 trillion KRW.

Tegosience is accelerating preparations to enter the U.S. market. They are conducting a survey to select a Contract Research Organization (CRO). By the end of the year, they plan to select a CRO and submit an Investigational New Drug (IND) application for phase 1 clinical trials to the U.S. Food and Drug Administration (FDA) early next year. The U.S. market is estimated to be about 10 trillion KRW annually.